Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Leukemia

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Br J Haematol

Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB

doi: 10.1111/bjh.19622

ASH 2024

Leukemia

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

EHA 2024

Leukemia

Insights into clinical outcomes of patients with R/R AML after treatment with gilteritinib

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Leukemia

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood

Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB

doi: 10.1182/blood.2024025154

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Lung Cancer

Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, Samjoo IA

doi: 10.1016/j.lungcan.2024.107816

Related content

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Insights into clinical outcomes of patients with R/R AML after treatment with gilteritinib

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Advancing Breast Cancer Treatment with Elacestrant

Results of TRODELVY® real-world data

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Results of TRODELVY^® real-world data